The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment

Anna L Goodman; Emily K Forbes; Andrew Richard Williams; Alexander D Douglas; Simone C de Cassan; Karolis Bauza; Sumi Biswas; Matthew D J Dicks; David Llewellyn; Anne C Moore; Chris J Janse; Blandine M Franke-Fayard; Sarah C Gilbert; Adrian V S Hill; Richard J Pleass; Simon J Draper

doi:10.1038/srep01706

The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment

Anna L Goodman, Emily K Forbes, Andrew Richard Williams, Alexander D Douglas, Simone C de Cassan, Karolis Bauza, Sumi Biswas, Matthew D J Dicks, David Llewellyn, Anne C Moore, Chris J Janse, Blandine M Franke-Fayard, Sarah C Gilbert, Adrian V S Hill, Richard J Pleass, Simon J Draper

20 Citationer (Scopus)

Abstract

Rodent malaria species Plasmodium yoelii and P. chabaudi have been widely used to validate vaccine approaches targeting blood-stage merozoite antigens. However, increasing data suggest the P. berghei rodent malaria may be able to circumvent vaccine-induced anti-merozoite responses. Here we confirm a failure to protect against P. berghei, despite successful antibody induction against leading merozoite antigens using protein-in-adjuvant or viral vectored vaccine delivery. No subunit vaccine approach showed efficacy in mice following immunization and challenge with the wild-type P. berghei strains ANKA or NK65, or against a chimeric parasite line encoding a merozoite antigen from P. falciparum. Protection was not improved in knockout mice lacking the inhibitory Fc receptor CD32b, nor against a Δsmac P. berghei parasite line with a non-sequestering phenotype. An improved understanding of the mechanisms responsible for protection, or failure of protection, against P. berghei merozoites could guide the development of an efficacious vaccine against P. falciparum.

Originalsprog	Engelsk
Tidsskrift	Scientific Reports
Vol/bind	3
Sider (fra-til)	1706
ISSN	2045-2322
DOI	https://doi.org/10.1038/srep01706
Status	Udgivet - 23 apr. 2013
Udgivet eksternt	Ja

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1038/srep01706

Citationsformater

Goodman, A. L., Forbes, E. K., Williams, A. R., Douglas, A. D., de Cassan, S. C., Bauza, K., Biswas, S., Dicks, M. D. J., Llewellyn, D., Moore, A. C., Janse, C. J., Franke-Fayard, B. M., Gilbert, S. C., Hill, A. V. S., Pleass, R. J., & Draper, S. J. (2013). The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment. Scientific Reports, 3, 1706. https://doi.org/10.1038/srep01706

Goodman, AL, Forbes, EK, Williams, AR, Douglas, AD, de Cassan, SC, Bauza, K, Biswas, S, Dicks, MDJ, Llewellyn, D, Moore, AC, Janse, CJ, Franke-Fayard, BM, Gilbert, SC, Hill, AVS, Pleass, RJ & Draper, SJ 2013, 'The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment', Scientific Reports, bind 3, s. 1706. https://doi.org/10.1038/srep01706

@article{8f6237c419fe46548630a546a3774cb5,

title = "The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment",

abstract = "Rodent malaria species Plasmodium yoelii and P. chabaudi have been widely used to validate vaccine approaches targeting blood-stage merozoite antigens. However, increasing data suggest the P. berghei rodent malaria may be able to circumvent vaccine-induced anti-merozoite responses. Here we confirm a failure to protect against P. berghei, despite successful antibody induction against leading merozoite antigens using protein-in-adjuvant or viral vectored vaccine delivery. No subunit vaccine approach showed efficacy in mice following immunization and challenge with the wild-type P. berghei strains ANKA or NK65, or against a chimeric parasite line encoding a merozoite antigen from P. falciparum. Protection was not improved in knockout mice lacking the inhibitory Fc receptor CD32b, nor against a Δsmac P. berghei parasite line with a non-sequestering phenotype. An improved understanding of the mechanisms responsible for protection, or failure of protection, against P. berghei merozoites could guide the development of an efficacious vaccine against P. falciparum.",

author = "Goodman, {Anna L} and Forbes, {Emily K} and Williams, {Andrew Richard} and Douglas, {Alexander D} and {de Cassan}, {Simone C} and Karolis Bauza and Sumi Biswas and Dicks, {Matthew D J} and David Llewellyn and Moore, {Anne C} and Janse, {Chris J} and Franke-Fayard, {Blandine M} and Gilbert, {Sarah C} and Hill, {Adrian V S} and Pleass, {Richard J} and Draper, {Simon J}",

year = "2013",

month = apr,

day = "23",

doi = "10.1038/srep01706",

language = "English",

volume = "3",

pages = "1706",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "nature publishing group",

}

TY - JOUR

T1 - The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment

AU - Goodman, Anna L

AU - Forbes, Emily K

AU - Williams, Andrew Richard

AU - Douglas, Alexander D

AU - de Cassan, Simone C

AU - Bauza, Karolis

AU - Biswas, Sumi

AU - Dicks, Matthew D J

AU - Llewellyn, David

AU - Moore, Anne C

AU - Janse, Chris J

AU - Franke-Fayard, Blandine M

AU - Gilbert, Sarah C

AU - Hill, Adrian V S

AU - Pleass, Richard J

AU - Draper, Simon J

PY - 2013/4/23

Y1 - 2013/4/23

N2 - Rodent malaria species Plasmodium yoelii and P. chabaudi have been widely used to validate vaccine approaches targeting blood-stage merozoite antigens. However, increasing data suggest the P. berghei rodent malaria may be able to circumvent vaccine-induced anti-merozoite responses. Here we confirm a failure to protect against P. berghei, despite successful antibody induction against leading merozoite antigens using protein-in-adjuvant or viral vectored vaccine delivery. No subunit vaccine approach showed efficacy in mice following immunization and challenge with the wild-type P. berghei strains ANKA or NK65, or against a chimeric parasite line encoding a merozoite antigen from P. falciparum. Protection was not improved in knockout mice lacking the inhibitory Fc receptor CD32b, nor against a Δsmac P. berghei parasite line with a non-sequestering phenotype. An improved understanding of the mechanisms responsible for protection, or failure of protection, against P. berghei merozoites could guide the development of an efficacious vaccine against P. falciparum.

AB - Rodent malaria species Plasmodium yoelii and P. chabaudi have been widely used to validate vaccine approaches targeting blood-stage merozoite antigens. However, increasing data suggest the P. berghei rodent malaria may be able to circumvent vaccine-induced anti-merozoite responses. Here we confirm a failure to protect against P. berghei, despite successful antibody induction against leading merozoite antigens using protein-in-adjuvant or viral vectored vaccine delivery. No subunit vaccine approach showed efficacy in mice following immunization and challenge with the wild-type P. berghei strains ANKA or NK65, or against a chimeric parasite line encoding a merozoite antigen from P. falciparum. Protection was not improved in knockout mice lacking the inhibitory Fc receptor CD32b, nor against a Δsmac P. berghei parasite line with a non-sequestering phenotype. An improved understanding of the mechanisms responsible for protection, or failure of protection, against P. berghei merozoites could guide the development of an efficacious vaccine against P. falciparum.

U2 - 10.1038/srep01706

DO - 10.1038/srep01706

M3 - Journal article

C2 - 23609325

SN - 2045-2322

VL - 3

SP - 1706

JO - Scientific Reports

JF - Scientific Reports

ER -

The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater